159 related articles for article (PubMed ID: 22552400)
1. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
3. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
Fukuda S; Oguri T; Kunii E; Sone K; Uemura T; Takakuwa O; Maeno K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Lung Cancer; 2016 Dec; 102():15-20. PubMed ID: 27987582
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Lustgarten DE; Deshpande C; Aggarwal C; Wang LC; Saloura V; Vachani A; Wang LP; Litzky L; Feldman M; Creaney J; Nowak AK; Langer C; Inghilleri S; Stella G; Albelda SM
J Thorac Oncol; 2013 Apr; 8(4):469-77. PubMed ID: 23486267
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy.
Hatakeyama Y; Kobayashi K; Nagano T; Tamura D; Yamamoto M; Tachihara M; Kotani Y; Nishimura Y
Cancer Lett; 2014 Feb; 343(1):74-9. PubMed ID: 24139969
[TBL] [Abstract][Full Text] [Related]
6. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
7. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
8. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
[TBL] [Abstract][Full Text] [Related]
9. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N
Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
11. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
Nannizzi S; Veal GJ; Giovannetti E; Mey V; Ricciardi S; Ottley CJ; Del Tacca M; Danesi R
Cancer Chemother Pharmacol; 2010 Aug; 66(3):547-58. PubMed ID: 20020129
[TBL] [Abstract][Full Text] [Related]
13. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
[TBL] [Abstract][Full Text] [Related]
14. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
Yang M; Fan WF; Pu XL; Liu FY; Meng LJ; Wang J
Oncol Lett; 2014 Jan; 7(1):227-232. PubMed ID: 24348854
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of pemetrexed in gastric cancer cells.
Kim JH; Lee KW; Jung Y; Kim TY; Ham HS; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
Cancer Sci; 2005 Jun; 96(6):365-71. PubMed ID: 15958060
[TBL] [Abstract][Full Text] [Related]
16. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.
Ozasa H; Oguri T; Uemura T; Miyazaki M; Maeno K; Sato S; Ueda R
Cancer Sci; 2010 Jan; 101(1):161-6. PubMed ID: 19811498
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.
Cui J; Zhang Y; Su D; Li T; Li Y
Thorac Cancer; 2018 Sep; 9(9):1156-1165. PubMed ID: 30047610
[TBL] [Abstract][Full Text] [Related]
18. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed‑resistant lung adenocarcinoma A549 cell line.
Yu Z; Li XM; Liu SH; Liu B; Gao CH; Hou X
Oncol Rep; 2014 Apr; 31(4):1818-24. PubMed ID: 24549863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
